While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

Ozempic (semaglutide) is prescribed for adults with ... The following dosing chart shows how your doctor may adjust your dosage of Ozempic. Dosage strength Starting dose Maintenance dose Dosing ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.

The FDA approved semaglutide (Ozempic) for diabetes in 2017 and weight ... the company generated $0.17 over the last year. The chart below shows that this metric has rapidly increased since ...

Novo Nordisk is actively exploring additional uses for semaglutide, including evaluating Wegovy for heart failure in diabetes and obesity patients and Ozempic as a treatment for T2D and chronic ...

A recent survey reveals the foods that people are less likely to eat once they start taking GLP-1 medications like Ozempic.

Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly ...

Compounded semaglutide and Ozempic are different products. While both may be used in people with type 2 diabetes, Ozempic is approved by the FDA, but compounded semaglutide is not. Compounded ...